AI‑driven protein design creates potent anti‑CRISPR inhibitors that block Cas13 activity, offering a new potential tool for safer, more controlled gene editing.

The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.

Corrosion inhibitors market to grow from $9.15 B in 2024 to $13.03 B by 2033, registering a 4.01% CAGR amid rising ...

Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities ...

MindWalk Holdings Corp. (NASDAQ:HYFT) ("MindWalk" or the "Company"), a Bio-Native AI therapeutic research and technology ...

Research published in the Journal of Personality by psychologists Barbora Nevicka and Constantine Sedikides found that ...

Corvus Pharmaceuticals, Inc. shares are up on solid soquelitinib AD phase 1 data: 75% hit EASI 75 at 200 mg BID, many ...

Most athletes play ping-pong to whet their competitive instincts or kill time, but what if it could improve performance?

Spherix Global Insights reports new findings from its inaugural Market Dynamix(TM): PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S.

With three new partnerships, 10x Genomics signals a move beyond research tools toward clinical diagnostics using its single-cell and spatial biology platforms.

BioCryst Pharmaceuticals is a Hold, as ORLADEYO faces mounting competitive pressures and the company pivots toward ...

Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of ...